CanSino Biologics (SHA:688185, HKG:6185) received a government income-related subsidy of 2.9 million yuan, according to a Tuesday filing with the Shanghai bourse.
The subsidy amount is equivalent to 10% of the company's audited net profit for its most recent fiscal year, the filing said.
The drug company's Hong Kong shares fell 5% while its Shanghai-traded shares slipped 3 on Tuesday afternoon.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.